CD7 and neoplasm: The Phase I clinical trial used a single-arm, open-label, dose-escalation (Level 1: 1×107cells/kg; Level 2: 2×107cells/kg; Level 3: 3×107cells/kg) design to evaluate the safety and tolerability of CD7-targeting CAR-T cells (RD13-01), and to observe its anti-tumor activity and pharmacokinetic properties.